Menu
Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in ...
(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada for NINLARO™ (ixazomib) capsules in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In Canada, it is estimated that approximately 7,500 people live with multiple myeloma. The approval was primarily based on the results of the final analysis of the pivotal Phase 3 trial, TOURMALINE-MM1, which demonstrated that NINLARO in combination with lenalidomide and dexamethasone significantly extended progression-free survival, with a manageable safety profile in patients with relapsed/refractory multiple myeloma. ...
Source : http://me-newswire.net//news/18447/en...
     
ACTUALITES
|
Jeudi 11 Septembre 2025 - 10:12 Tchad : ARCHI, fer de lance de la microfinance islamique au Tchad |
Pour toute information, contactez-nous au : +(235) 99267667 ; 62883277 ; 66267667 (Bureau N'Djamena)
TRIBUNE & DEBATS
POINT DE VUE - 29/08/2025 - Dr. Rokia Ahjou
La stratégie marocaine contre le terrorisme : une approche globale et multidimensionnelle
Tchad : Abderaman Koulamallah appelle à la réconciliation et à une mémoire partagée
25/08/2025 - Peter Kum
ANALYSE - 29/08/2025 - Nguessitta Djimtengaye William
Tchad : Les enfants travailleurs face à l'indifférence
Tchad : Réussite et richesse, un débat entre deux visions
25/08/2025 - Achta Mahamat
REACTION - 23/08/2025 - Albadour Acyl Ahmat Akhabach
"Par le regard du Tchadien", tribune de Albadour Acyl Ahmat Akhabach
Politique : Maaouiya Abderahim Bremé appelle à la cohésion et au respect des valeurs du parti MPS
13/08/2025 - Maaouiya Abderahim Bremé
|
|